Recommended
Recommended
Recent Quotes
My Watchlist
Indicators
Local Stocks
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

125.78 +0.55 (+0.44%)
Official Closing Price Updated: 7:00 PM EDT, Apr 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 9,403,980
Open 125.65
Bid (Size) 124.12 (1)
Ask (Size) 126.96 (1)
Prev. Close 125.23
Today's Range 124.89 - 126.12
52wk Range 99.14 - 133.10
Shares Outstanding 2,531,374,696
Dividend Yield 2.32%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Unveiling 17 Analyst Insights On Merck & Co
Via Benzinga
Market Whales and Their Recent Bets on MRK Options
Via Benzinga

Performance

YTD
+11.07%
+11.07%
1 Month
+1.56%
+1.56%
3 Month
+5.80%
+5.80%
6 Month
+22.51%
+22.51%
1 Year
+10.17%
+10.17%

More News

Read More
Coming FDA Approvals Could Send These 3 Drug Stocks Soaring
Via InvestorPlace
Exposures Product Safety
3 Dow Stocks to Buy Now: Q2 Edition
Via InvestorPlace
Topics Stocks
Exposures US Equities
Healthcare Stocks Are Lagging With Big Earnings Weeks Ahead
Via Talk Markets
Better Growth Play: Merck or The Vanguard Growth Index Fund?
Via The Motley Fool
When you look at NYSE:MRK, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
Via Chartmill
Understanding Merck & Co's Position In Pharmaceuticals Industry Compared To Competitors
Via Benzinga
2 Dividend Stocks to Buy and Hold Forever
Via The Motley Fool
Merck Paid $208 Million to Stop Its Drugs From Working. Here's Why That's Bullish.
Via The Motley Fool
1 New Green Flag for Moderna and Merck Stock
Via The Motley Fool
7 A-Rated Aggressive Biotech Stocks to Bet On in 2024
Via InvestorPlace
Declining COVID-19 Vaccine Sales Pinches Moderna, Pauses Kenya Vaccine Plant Plans
Via Benzinga
Exposures COVID-19
The $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today
Via InvestorPlace
Market Whales and Their Recent Bets on MRK Options
Via Benzinga
Vaccine Player Vaxcyte Has Advantage Over Pfizer, Merck's Pneumococcal Shots - Analyst Says
Via Benzinga
The Pharmaceutical Industry Finds Itself At A Historical Crossroads
Via Benzinga
Why Is Moderna Stock Trading Higher On Tuesday?
Via Benzinga
Golden Years Gainers: 3 Stocks to Fund Your Dream Retirement
Via InvestorPlace
Topics Retirement
Exposures Pension
Down 75%. Is Agenus Stock a Buy on the Dip?
Via The Motley Fool
The 3 Most Undervalued S&P 500 Stocks to Buy in April 2024
Via InvestorPlace
Topics Economy Stocks
Exposures Economy US Equities
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Cancer-Focused eFFECTOR Therapeutics Shelves Development Of Lung Cancer Candidate After Disappointing Data
Via Benzinga
Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer
From Merck & Co., Inc.
Via Business Wire
REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer
From Daiichi Sankyo
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.